Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat
- 1 September 2009
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 297 (3) , H1128-H1139
Abstract
We have recently reported that transgenic (mRen2)27 rats (Ren2 rats) exhibit pulmonary arterial hypertension (PAH), which is, in part, mediated by oxidative stress. Since 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) exhibit beneficial vascular effects independent of cholesterol synthesis, we hypothesized that rosuvastatin (RSV) treatment ameliorates PAH and pulmonary vascular remodeling in Ren2 rats, in part, by reducing oxidative stress. Six-week-old male Ren2 and Sprague-Dawley rats received RSV (10 mg·kg−1·day−1 ip) or vehicle for 3 wk. After treatment, right ventricular systolic pressure (RVSP) and mean arterial pressure (MAP) were measured. To evaluate treatment effects on pulmonary arteriole remodeling, morphometric analyses were performed to quantitate medial thickening and cell proliferation, whereas whole lung samples were used to quantitate the levels of 3-nitrotyrosine, superoxide, stable nitric oxide (NO) metabolites [nitrates and nitrites (NOx)], and expression of NO synthase isoforms. In the Ren2 rat, RVSP is normal at 5 wk of age, PAH develops between 5 and 7 wk of age, and the elevated pressure is maintained with little variation through 13 wk. At 8 wk of age, left ventricular function and blood gases were normal in the Ren2 rat. Ren2 rats exhibited elevations in medial hypertrophy due to smooth muscle cell proliferation, 3-nitrotyrosine, NOx, NADPH oxidase activity, and endothelial NO synthase expression compared with Sprague-Dawley rats. RSV significantly blunted the increase in RVSP but did not reduce MAP in the Ren2 rat; additionally, RSV significantly attenuated the elevated parameters examined in the Ren2 rat. These data suggest that statins may be a clinically viable adjunct treatment of PAH through reducing peroxynitrite formation.Keywords
This publication has 58 references indexed in Scilit:
- Effect of Rosuvastatin on Cardiac Remodeling, Function, and Progression to Heart Failure in Hypertensive Heart With Established Left Ventricular HypertrophyHypertension, 2009
- Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertensionBritish Journal of Pharmacology, 2008
- Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 ratAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin TreatmentHypertension, 2008
- Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 ratAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT 1 and AT 2 receptorsProceedings of the National Academy of Sciences, 2006
- Reactive oxygen species signaling in vascular smooth muscle cellsCardiovascular Research, 2006
- Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivoBiochemical and Biophysical Research Communications, 2006
- Pulmonary vascular iNOS induction participates in the onset of chronic hypoxic pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophyJournal of Clinical Investigation, 2001